A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets
Firm Highlights LAI Olanzapine, As Trial Results Come Nine Months Ahead Of Schedule
Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.
